Webinar: Preclinical Considerations for Cell-Based Immunotherapies -- May 30 at 11 am ET

Webinar: Preclinical Considerations for Cell-Based Immunotherapies

Hosted by the American College of Toxicology in Collaboration with the Teratology Society, British Toxicology Society, and Society of Toxicologic Pathology

Thursday, May 30, 2018 at 11 am Eastern  (this is a new date!)

Registration Link

Speaker: Allen K. Wensky, PhD Biologist, Master Pharmacology/Toxicology Reviewer Office of Tissues and Advanced Therapies (OTAT) Pharmacology and Toxicology Branch 2 (PTB2)

Webinar Abstract: The general content and format of pharmacology/toxicology information to be included in the submission of an IND can be found in 21 CFR 312.23 (a)(8). The regulation states that “The kind, duration, and scope of animal and other tests required vary with the duration and nature of the proposed clinical investigations.” The design and conduct of preclinical pharmacological and toxicological studies are thus important to inform regulatory decisions regarding the administration of an investigational cellular immunotherapy product in humans. These considerations will be discussed in addition to available FDA guidances, including FDA “Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products”. Lastly, the presentation will highlight the mechanisms for early communication with pharmacology/toxicology staff in CBER’s Office of Tissues and Advanced Therapies (OTAT) to obtain feedback on the preclinical development program.

This webinar is free but registration is required: Registration Link

Recent Stories
Request for participation in multisector thyroid hormone survey & historical control data collection

Teratology Society Privacy Policy Update - May 2018

Cast Your Vote for Teratology Leadership before Midnight Tuesday May 22